Upcoming SMi Conference Puts Spotlight On Biosimilar Policy & Commercialization Strategies

It's without doubts that the biosimilars market present lucrative opportunities for pharmaceutical and biotech companies. Over the last 12 months, market participants have taken revolutionary steps in the U.S. to facilitate commercialization. It is now time to meet your industry colleagues to discuss how to commercialize biosimilars and strike up industry partnerships; howinterchangeability will impact biosimilars; regulatory updates,and much more.

SMi Group is delighted to have EdricEngert, Senior Vice President, Biosimilars from Teva Pharmaceuticals discussing Biosimilars – from aspiration to operations at the 3rd annual Biosimilars North America conference on November 16 and 17, 2016. Edric will focus on corporate strategy, portfolio strategy, and organizational implications.

Considerations for commercial success will be presented by Molly Burich, associate director, public policy – biosimilars, pipeline, reimbursement, BoehringerIngelheim Pharmaceuticals. Molly will answer the big question of reimbursement of biosimilars in the U.S.:What challenges does the future pose?

Furthermore, Brad Jordan, director, regulatory affairs and R&D policy, Amgen,will be discussing regulatory concerns for interchangeability. The questions to be answered: What’s in a name? Differentiating European and U.S. terms and policies. What are the concerns? Medically-guided switching vs. pharmacy substitution. What’s the standard? Survey of perspectives from policy makers and industry.

Day one will address regulatory updates andthe lessons learned in Europe and worldwide. Day two will explore the technological developments, commercialization strategies, and market development, including presentations and an overview from Europe, Canada, China,and more.

Other speakers will include: Sandoz, Norwegian Medicines Agency, Vizient, Janssen R&D, Abzena, Harvest Moon Pharmaceuticals, Wyatt Health Management, Schwegman Lundberg Woessner, Abpro-US.

To find out more about the event please visit: www.biosimilars-northamerica.com

 About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in business-to-business conferences, workshops, Masterclasses, and online communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance, and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk